|Day Low/High||0.95 / 1.01|
|52 Wk Low/High||0.49 / 3.59|
AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec.
AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2013 financial results and outlined its 2014 strategic plan and financial guidance.
AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014.
AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the companies will end their worldwide collaboration and license agreement for the development and commercialization of investigational...
AVEO Oncology (NASDAQ: AVEO) today announced that AVEO and Astellas Pharma Inc.
By any number of measures this market is getting pricey.
The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.
AVEO Oncology (NASDAQ: AVEO) today announced that data from a planned interim analysis of the Phase 2 BATON ( Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer...
Amarin, Ariad, Vical, Dendreon and Aveo. You get to decide which CEO deserves to wear the badge of shame.
AVEO Oncology (NASDAQ: AVEO) today reported its third quarter 2013 financial results.
AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2013 at 12:55 p.
AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Canaccord Genuity 33 rd Annual Growth Conference on Thursday, August 15, 2013 at 2:00 p.
AVEO Oncology (NASDAQ: AVEO) today reported second quarter 2013 financial results.
The most recent short interest data was recently released by the NASDAQ for the 06/28/2013 settlement date, and AVEO Pharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 5.59 "days to cover" versus the median component at 3.80.
The FDA has let down renal cancer patients with its Tivozanib decision.
Scotts Miracle-Gro CEO swears like a sailor, Aveo sinks like the Titanic, Sprint's captain tries to capsize the Dish CEO's offer and more.
Scotts Miracle-No!, Synta's Sorrow and Google's Porn Problem highlight Gregg Greenberg's 5 Dumbest list this week.
Aveo's next chance to resurrect its flailing cancer drug will come in 2014/2015 with breast cancer study data.
The failure of a kidney cancer drug won't stop Aveo executives from cashing future paychecks.
Status quo reigns at struggling Aveo's shareholder meeting, but will planned changes include executive turnover?
An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.
At some point, investors will give Aveo credit for tivozanib, says David Sobek.
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Strategists predict equity markets will be propelled higher with one warning of a bubble poised to be popped.
Heads need to roll at Aveo because of the FDA's thrashing of the company's kidney cancer drug.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.